EGFR and neoplasm: This means that even after totally depleting EGFRvIII expressing populations of cells specifically, other tumor sub-clones with alternative mutations could be selected for, maintaining the tumor population and allowing functional resistance to EGFR-targeting therapies, and inhibitors of other ERBB family members may also be required for down-regulation of downstream elements (86, 91).